GeneralConnection.com ➔ Dictionary
Dictionary Search

factor xi

Synonyms

Noun

1. plasma thromboplastin antecedent

2. factor XI, coagulation factor, clotting factor

Usage
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism - Nature
Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS - American Heart Association Journals
Anti-Factor XI Anticoagulants: Breakthrough or Bust? - Medscape
Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI - The New England Journal of Medicine
New Factor XI inhibitor shows superior safety in treating atrial fibrillation - News-Medical
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders - Business Wire
Abelacimab: the next frontier in safer anticoagulation therapy - Drug Target Review
Factor Xa and Factor XI Inhibitors: What Lies Ahead for Anticoagulants - The Cardiology Advisor
NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear - TCTMD.com
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - GlobeNewswire
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors - Frontiers
Novartis pays $925M to reel in a startup it helped launch - BioPharma Dive
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation - Pharmacy Times
What Now for Factor XI Inhibitors in AF? - Medscape
Asundexian versus Apixaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism - Frontiers
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Factors XI and XII as Targets for New Anticoagulants - Frontiers
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - GlobeNewswire
The effect of coagulation traits on the risk of retinal vein occlusion: a mendelian randomization study - Nature
ISTH announces launch of new global education initiative in factor XI/XIa inhibition - PR Newswire
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial - Fierce Biotech
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence - Frontiers
Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation - Business Wire
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate - Fierce Biotech
Regeneron Will Move Two Factor XI Agents Into Phase III - insights.citeline.com
Regeneron forges ahead in factor XI despite field’s mixed results - Endpoints News
Effects of storage time and temperature on coagulation factor and natural anticoagulant activities in healthy individuals - Nature
Asundexian for AF? More Details on the Sinking of OCEANIC-AF - TCTMD.com
Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib - MedPage Today
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition - BioSpace
Clinical Trial Opportunity for Afib Patients Who Don’t Take an Anticoagulant - National Blood Clot Alliance
Novartis buys Blackstone's Anthos for up to $3.1 billion - Reuters
Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab - AJMC
Abstract 4143980: Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial - American Heart Association Journals
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Blackstone
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation - The Pharmaceutical Journal
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban - HCPLive
Jan 24, 2025 This Week in Cardiology Podcast - Medscape
Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed? - Endpoints News
Figure 1 Factor XI (FXI) and its activated form (FXa) affect fibrin... - ResearchGate
Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients - News-Medical
Regeneron advances anticoagulant antibody program - The Pharma Letter
Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial - HCPLive
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio - geneonline.com
New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes - Fierce Biotech
Biologic demonstrates “tremendous” potential advance in atrial fibrillation - European Pharmaceutical Review
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos - Endpoints News
(PDF) Factor XI Deficiency: A Rare Cause of Prolonged Bleeding in a Post-Operative Patient - ResearchGate
Pharmacology and Clinical Development of Factor XI Inhibitors | Circulation - American Heart Association Journals
Sites of Factor XI Inhibition for Drugs in Development. Some inhibitors... - ResearchGate
Further strong data for Anthos’ abelacimab in atrial fibrillation - The Pharma Letter
Role of factor XI in hemostasis (see text). Factor XI plays an... - ResearchGate
Figure 1 Mechanism of action of factor XI(a) inhibitors. Adapted... - ResearchGate
A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin–Angiotensin Systems - Frontiers
Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding - HCPLive
Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib - HealthDay
Factor XI Deficiency: Practice Essentials, Background, Pathophysiology - Medscape
What Is the Future of Factor XI Inhibitors? - American Heart Association Journals
Stopping abelacimab may not be necessary before invasive procedures - Healio
Role of factor XI in thrombosis. Factor XI is particularly important... - ResearchGate
FIGURE 1: Rotational thromboelastometry (ROTEM) traces of the clinical... - ResearchGate
New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors - American Heart Association Journals
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes - American Heart Association Journals
Factor XI Inhibitors: The Promise of a Truly Safe Anticoagulant? - Medscape
Pharmacology and Clinical Development of Factor XI Inhibitors | Circulation - American Heart Association Journals
‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar - Endpoints News
Q&A: Failure of OCEANIC-AF trial may not dampen future of factor XI/XIa inhibitors - Healio
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial - AJMC
A Case of Myxedema Edema in a Patient With Factors XI and XII Deficiency and Sepsis: Unveiling Complications and Management Strategies - Cureus
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial - Nature
Feedback activation of factor XI by thrombin does not occur in plasma - PNAS
New anti-clotting medication reduces bleeding among people with atrial fibrillation - www.heart.org
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics' novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patient - The Manila Times
Liver-derived factor XI protects against HFpEF - Nature
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial - American Heart Association Journals
Investigational Anticoagulant May be Cost-Effective - Managed Healthcare Executive
Abelacimab for Prevention of Venous Thromboembolism - The New England Journal of Medicine
Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial - Healio
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke - American Heart Association Journals
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale - Nature
Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure - Science | AAAS
Innovation and Technology : Factor XI Inhibitors - Citigroup
Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients? | Circulation - American Heart Association Journals
Representation of factor XI and factor XIa inhibitors in varied... - ResearchGate
Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma - PNAS
AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa - American Heart Association Journals
Factor XI Structure and Function. Based on crystallographic structure... - ResearchGate
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation - Business Wire
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI) - American Heart Association Journals
Targeting Factor XI to Prevent Thrombosis | Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals
Merging Biocatalysis, Flow, and Surfactant Chemistry: Innovative Synthesis of an FXI (Factor XI) Inhibitor - ACS Publications
The circulatory levels of coagulation factors in HF Source: Designed by... - ResearchGate
Forest Plot for FXI inhibitors vs enoxaparin of (A) All-bleeding events... - ResearchGate
Abstract 12360: Association of Coagulation Factor XI Levels With Cardiac Function and Cardiovascular Events: The Atherosclerosis Risk in Communities (ARIC) Study - American Heart Association Journals
Asundexian’s Lack of Efficacy Sinks OCEANIC-AF - TCTMD.com
Foreign Language Equivalents
Foreign Language Equivalents of 'factor xi'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
,   factot xi,   faactor xi,   factor ix,   factorxi,   facotr xi,   facror xi,   factor ci,   factor xxi,   fsctor xi,   factpr xi,   factoe xi,   fcator xi,   factir xi,   factor xii,   actor xi,   factor zi,   dactor xi,   factro xi,   facctor xi,   facor xi,   fator xi,   factor xu,   factor i,   factor x,   faxtor xi,   facttor xi,   ffactor xi,   facyor xi,   factorx i,   factorr xi,   factr xi,   facto rxi,   factoor xi,   facter xi,   afctor xi,   gactor xi,   facto xi,   fatcor xi,   factor xo,   fctor xi,   favtor xi,   factor xi
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z